Rejuvenate Bio Raises $6 Million to Advance Gene Therapy Programs

Rejuvenate Bio, a biotechnology company based in San Diego, has secured $6 million in financing to support the development of gene therapies for age-related and chronic diseases.

The funding round was led by VCapital. Existing and new investors, including Merck Animal Health, Kendall Capital Partners, Connecticut Innovations, and Digitalis, also participated.

Funding to Support Gene Therapy Development

The company plans to use the capital to further develop its technology platform and expand its pipeline of gene therapy candidates. Its current focus includes treatments designed to address chronic and age-associated conditions in companion animals.

Rejuvenate Bio develops gene therapies that target biological pathways linked to aging and chronic disease. The company combines gene delivery technologies with advances in translational biology to create treatments that may improve health outcomes in animals. In the longer term, the company also aims to explore applications for human health.

Collaboration with Merck Animal Health

Alongside the financing, Rejuvenate Bio announced a strategic research and development collaboration with Merck Animal Health.

The partnership will focus on advancing a new gene therapy program for animal health. Through the collaboration, the companies plan to support research efforts and evaluate potential therapeutic applications for companion animals.

Expanding Animal Health Innovation

The latest funding provides additional resources for Rejuvenate Bio as it continues to develop therapies for chronic diseases and age-related conditions. The company expects the investment and industry collaboration to support ongoing research and product development initiatives within the animal health sector.

Recently funded and expanding your team?

WorkNation helps startups and growth-stage companies hire top talent faster.

📩 hiring@worknation.buzz | 🌐 worknation.buzz/hiring-solutions